sur The Charcot-Marie-Tooth Association
CMTA Board Welcomes New Directors Bernard Coulie and Kevin Marks
The Charcot-Marie-Tooth Association (CMTA) announced the addition of Bernard Coulie, M.D., Ph.D., and Kevin Marks to its Board of Directors, bringing in their vast experience in corporate, drug development, and compliance. Coulie, the CEO and President of Pliant Therapeutics, has over 20 years in the biopharmaceutical industry and a personal connection to CMT through his son. Kevin Marks comes with a strong legal background in the drug development sector and is currently the Chief Legal Officer at the Parker Institute for Cancer Immunotherapy.
This move aligns with CMTA’s ongoing mission to push forward in finding treatments and ultimately a cure for Charcot-Marie-Tooth disease, a rare condition that affects one in every 2,500 people. Gilles Bouchard, the Chairman of the CMTA Board, expressed enthusiasm for the board’s new additions, underscoring the value of their expertise in advancing treatment development. The association also extends its gratitude to the outgoing board members for their years of service, now transitioning to special advisors.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Charcot-Marie-Tooth Association